IntellaTip MiFi XP Ablation Catheter Trial (MiFi-CTI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01730807
Recruitment Status : Completed
First Posted : November 21, 2012
Last Update Posted : May 4, 2017
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
A study to assess the performance of a new catheter design for the treatment of Atrial Flutter.

Condition or disease Intervention/treatment Phase
Atrial Flutter Device: IntellaTip MiFi XP Catheter Not Applicable

Detailed Description:
A prospective, non-blinded, single arm, single center study designed to assess the performance of the IntellaTip MiFi XP Ablation Catheter for the treatment of recurrent or sustained type I atrial Flutter.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: IntellaTip MiFi XP Ablation Catheters First in Human Use Trial
Study Start Date : March 2013
Actual Primary Completion Date : February 2014
Actual Study Completion Date : January 2015

Arm Intervention/treatment
Experimental: IntellaTip XP MiFi
Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
Device: IntellaTip MiFi XP Catheter
Temperature controlled ablation catheter

Primary Outcome Measures :
  1. Acute Procedural Success [ Time Frame: one day ]
    The Demonstration of bi-directional isthmus block at the end of the ablation procedure

Secondary Outcome Measures :
  1. Complication Rate at procedure [ Time Frame: 7 days ]
    Determine major complications in patients exposed to the device, which occur within 7 days of the procedure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 or older
  • indicated for ablation for Atrial Flutter

Exclusion Criteria:

  • Thrombus
  • Recent MI/cardiac revascularization
  • Prosthetic Valves
  • recent ablation for atrial flutter
  • atrial flutter with reversible cause
  • Class IV HF

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01730807

Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5001
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Prashanthan Sanders, MD Royal Adelaide Hospital

Responsible Party: Boston Scientific Corporation Identifier: NCT01730807     History of Changes
Other Study ID Numbers: MiFi-CTI
First Posted: November 21, 2012    Key Record Dates
Last Update Posted: May 4, 2017
Last Verified: May 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Boston Scientific Corporation:
Atrial Flutter
Type I Atrial Flutter
Atrial Arrhythmia

Additional relevant MeSH terms:
Atrial Flutter
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes